drugset / Trial / NCT04179110
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate response and survival of treatment with the combination of pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune checkpoint inhibitor treatment.
Timeline
- Start
- 2020-09-18
- Primary completion
- 2022-12-15
- Completion
- 2023-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Ramucirumab | Monoclonal antibody | 10 mg/kg | — |